DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema

Information source: Hallym University Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetic Macular Edema

Intervention: Intravitreal injection (Procedure)

Phase: N/A

Status: Completed

Sponsored by: Hallym University Medical Center

Summary

One of the most frequent complications of diabetic retinopathy is diabetic macular edema. Recently, intravitreal bevacizumab and intravitreal triamcinolone were the most popular therapeutic modalities. However, as the long term effects of intravitreal bevacizumab and intravitreal triamcinolone on visual acuity and macular thickness have not been compared, it was the purpose of the present study to compare these treatment effects

Clinical Details

Official title: Comparative Treatment of Intravitreal Bevacizumab and Triamcinolone Acetonide on Diabetic Macular Edema

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: Visual acuity

Secondary outcome: Central macular thickness

Detailed description: Randomization of intravitreal bevacizumab, intravitreal triamcinolone, intravitreal bevacizumab with triamcinolone on eyes with diabetic macular edema

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diabetic macular edema (central macular thickness greater than 300 mm on optical

coherence tomography ) Exclusion Criteria:

- history of glaucoma or ocular hypertension (defined as an intraocular pressure higher

than 22 mmHg)

- an ocular condition (other than diabetes) that, in the opinion of the investigator,

might affect macular oedema or alter visual acuity during the course of the study (e. g. retinal vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc.)

- systemic corticosteroid therapy history of thromboembolic event (including myocardial

infarction or cerebral vascular accident)

- major surgery within the prior 6 months or planned within the next 28 days

Locations and Contacts

JiWon Lim, Chuncheon, Korea, Republic of
Additional Information

Starting date: March 2009
Last updated: April 26, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017